Nanotechnology to Overcome World's Most Critical Health Issues: Liposomes and beyond-a Themed Issue Dedicated to Professor Yechezkel Barenholz
This Special Issue focuses on a variety of nanotechnology platforms, including liposomes, which are used for the delivery of therapeutics and vaccines in order to solve the world's most critical health issues and to support environmental sustainability.
Saved in:
| Other Authors: | , |
|---|---|
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2023
|
| Subjects: | |
| Online Access: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_112487 | ||
| 005 | 20230808 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20230808s2023 xx |||||o ||| 0|eng d | ||
| 020 | |a books978-3-0365-8167-5 | ||
| 020 | |a 9783036581668 | ||
| 020 | |a 9783036581675 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.3390/books978-3-0365-8167-5 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a TB |2 bicssc | |
| 072 | 7 | |a TCB |2 bicssc | |
| 100 | 1 | |a Dobrovolskaia, Marina |4 edt | |
| 700 | 1 | |a Afonin, Kirill |4 edt | |
| 700 | 1 | |a Dobrovolskaia, Marina |4 oth | |
| 700 | 1 | |a Afonin, Kirill |4 oth | |
| 245 | 1 | 0 | |a Nanotechnology to Overcome World's Most Critical Health Issues: Liposomes and beyond-a Themed Issue Dedicated to Professor Yechezkel Barenholz |
| 260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2023 | ||
| 300 | |a 1 electronic resource (178 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a This Special Issue focuses on a variety of nanotechnology platforms, including liposomes, which are used for the delivery of therapeutics and vaccines in order to solve the world's most critical health issues and to support environmental sustainability. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Technology: general issues |2 bicssc | |
| 650 | 7 | |a Biotechnology |2 bicssc | |
| 653 | |a pickering emulsions | ||
| 653 | |a onychomycosis topical treatment | ||
| 653 | |a tioconazole | ||
| 653 | |a tea tree essential oil | ||
| 653 | |a antifungal activity | ||
| 653 | |a chloroquine | ||
| 653 | |a hydroxychloroquine | ||
| 653 | |a nanomedicine | ||
| 653 | |a nanoformulation | ||
| 653 | |a ureter imaging | ||
| 653 | |a fluorescence-guided surgery | ||
| 653 | |a near-infrared dye | ||
| 653 | |a PEG pharmacokinetics | ||
| 653 | |a nucleic acid nanoparticles (NANPs) | ||
| 653 | |a immunorecognition | ||
| 653 | |a immunoreaction | ||
| 653 | |a Toll-like receptors | ||
| 653 | |a cytokine storm syndrome | ||
| 653 | |a complement activation-related pseudoallergy | ||
| 653 | |a CD38 | ||
| 653 | |a drug-free macromolecular therapeutics | ||
| 653 | |a human serum albumin conjugates | ||
| 653 | |a morpholino oligonucleotides | ||
| 653 | |a daratumumab | ||
| 653 | |a isatuximab | ||
| 653 | |a multiple myeloma | ||
| 653 | |a lymphoma | ||
| 653 | |a immunity | ||
| 653 | |a bionanopharmaceuticals | ||
| 653 | |a impurities | ||
| 653 | |a immunotoxicity | ||
| 653 | |a immunogenicity | ||
| 653 | |a bioassays | ||
| 653 | |a cytokines | ||
| 653 | |a innate immunity | ||
| 653 | |a peptides | ||
| 653 | |a teriparatide | ||
| 653 | |a pancreatic cancer | ||
| 653 | |a prodrug nanoparticles | ||
| 653 | |a combination treatment | ||
| 653 | |a synergistic effect | ||
| 653 | |a nucleic acid nanoparticle | ||
| 653 | |a RNA motif | ||
| 653 | |a RNA domain | ||
| 653 | |a SHAPE analysis | ||
| 653 | |a nucleic acid nanoparticles | ||
| 653 | |a lipofectamine | ||
| 653 | |a cytokine | ||
| 653 | |a interferons | ||
| 653 | |a n/a | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/7602 |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/112487 |7 0 |z DOAB: description of the publication |